The Human Variable 

CRISPR²™ (CRISPR Readiness Index, Stabilization, Personalized Recovery) introduces a state-dependent framework for gene editing in complex chronic disease. Unlike conventional models that assume biological stability, CRISPR² integrates patient readiness, environmental exposure, temporal symptom dynamics, and recovery conditions to guide when and how intervention occurs. This approach expands therapeutic reach across severity levels, improves interpretation of outcomes in vari

Personalized CRISPR Remission™ for ME/CFS explores customized, individualized gene-editing strategies based on immune state, environmental factors, and neuroimmune instability to enable state-dependent remission in infection-associated chronic conditions. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-system condition. Personalized CRISPR Remission™ for MECFS is not limited to one editing event or one delivery paradigm.

Personalized CRISPR Remission™ for sarcoidosis introduces a state-dependent precision medicine framework integrating immune biology, environmental exposure, safety modeling, and CYNAERA predictive systems to improve durable response and reduce variability.

CYNAERA’s Personalized CRISPR Remission™ in melanoma integrates PD-1 edited TIL therapy, tumor microenvironment alignment, and VitalGuard™ modeling to improve durable response prediction.

A new framework for disease prevalence estimation, the Diagnostic Multiplier™ (DM™) adjusts for underdiagnosis, diagnostic variability, and environmental exposure across conditions.

CRISPR Remission™ for Lyme disease introduces a personalized CRISPR framework integrating environmental burden, immune variability, and state-dependent intervention to address persistent Lyme and post-treatment Lyme disease.